We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About ACCB Biotech Stock

Invest in or calculate the value of your shares in ACCB Biotech or other pre-IPO companies through EquityZen's platform.

Get Started

ACCB Biotech Stock (ACBI)

Beijing ACCB Biotech is focused on the R&D of cancer detection methods through the application of molecular biology technologies.

About ACCB Biotech Stock

Founded

2004

Industries

Travel and Tourism, Manufacturing, Space

Beijing ACCB Biotech Ltd. (雅康博生物) is focused on the research and development of cancer detection methods through the application of molecular biology technologies. Based on the concept of personalized therapy, the company provides detection services that include early-cancer screening, drug selection, effect tracking, prognostic evaluation, transfer and recurrence monitoring, and other testing services. ACCB Biotech’s product series include EnzymAct, Baikangan, Gene 21 of Breast Cancer, automated workstation for nucleic acid extraction, and more. The company now has production, research and development, and service facilities of more than 3,000 square meters, and its cleanliness attains the criteria of 10,000 grades. In June, 2009, EnzymAct® was successfully approved by the State Food and Drug Administration.

ACCB Biotech Management

Leadership team at ACCB Biotech

CEO

Junpu Xu

Co-Founder & CTO

Biao He

Locked Features

Join now and verify your accreditation status to gain access to:

  • ACCB Biotech Current Valuation
  • ACCB Biotech Stock Price
  • ACCB Biotech Management
  • Available deals in ACCB Biotech and all other companies with relevant Deal Offering documents
  • EquityZen's proprietary data and insights, which may include
    • ACCB Biotech Cap Table and Funding History by Share Class and Liquidity Preferences
    • ACCB Biotech Revenue and Financials
    • ACCB Biotech Highlights
    • ACCB Biotech Business Model
    • ACCB Biotech Risk Factors
  • ACCB Biotech Research Report from SACRA Research
Join Now

Trading ACCB Biotech Stock

How to invest in ACCB Biotech stock?

Accredited investors can buy pre-IPO stock in companies like ACCB Biotech through EquityZen funds. These investments are made available by existing ACCB Biotech shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell ACCB Biotech stock?

Shareholders can sell their ACCB Biotech stock through EquityZen's private company marketplace. EquityZen's network includes over 410K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 50K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."